Resources from the same session
2374 - IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
Presenter: Martin Reck
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Abstract
Slides
Webcast
2610 - Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538
Presenter: Jeffrey Bogart
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Abstract
Slides
Webcast
3167 - Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Abstract
Slides
Webcast
4773 - A phase 1 study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)
Presenter: Christine Hann
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Abstract
Slides
Webcast
3837 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
Presenter: Luis Paz-Ares
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC) - Invited Discussant 1738O and 1739O
Presenter: Rafal Dziadziuszko
Session: Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)
Resources:
Slides
Webcast